SynAct Pharma Logo

SynAct Pharma

ISIN: SE0008241491 | Ticker: SYNACT | LEI: 549300RRYIEFEQ72N546
Sector: Health CareSub-Industry: Biotechnology
Country: Sweden

About SynAct Pharma

Company Description

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation. SynAct’s therapeutics are designed to selectively provide anti-inflammatory and pro-resolution effects, so that patients can achieve immune balance and live beyond their inflammation.

AP1189, our product candidate selectively stimulates the melanocortin receptors involved in anti-inflammatory and pro-resolution effects without causing immunosuppression that is associated with most of the available anti-inflammatory therapies. These immunosuppressive approaches can lead to opportunistic infections and other serious side effects.

Year founded

2012

Served area

Worldwide

Headquarters

Medicon Village AB Scheelevägen 2, 22381 Lund – Sweden

Financial statements

Download as Excel
Line item in (sek) 02.01.2021 01.01.2022 02.01.2022 01.01.2023
Assets N/A 38,369,000.00 N/A 142,597,000.00
Noncurrent Assets N/A 3,454,000.00 N/A 2,365,000.00
Current Assets N/A 34,916,000.00 N/A 140,232,000.00
Current Prepaid Expenses N/A 247,000.00 N/A 17,293,000.00
Other Current Receivables N/A 3,107,000.00 N/A 6,464,000.00
Current Tax Assets Current N/A 7,564,000.00 N/A 8,231,000.00
Cash and cash equivalents 14,548,000.00 23,997,000.00 23,997,000.00 108,245,000.00
Equity And Liabilities N/A 38,369,000.00 N/A 142,597,000.00
Equity 15,868,000.00 20,869,000.00 20,869,000.00 126,520,000.00
Issued Capital N/A 3,251,000.00 N/A 3,706,000.00
Retained Earnings N/A -175,585,000.00 N/A -274,790,000.00
Additional Paidin Capital N/A 193,602,000.00 N/A 394,839,000.00
Equity Attributable To Owners Of Parent N/A 20,869,000.00 N/A 126,520,000.00
Noncurrent Liabilities N/A 2,110,000.00 N/A 1,064,000.00
Current Liabilities N/A 15,390,000.00 N/A 15,013,000.00
Trade And Other Current Payables N/A 4,254,000.00 N/A 4,723,000.00
Accruals Classified As Current N/A 7,889,000.00 N/A 4,909,000.00
Other Current Liabilities N/A 2,267,000.00 N/A 4,381,000.00
Line item in (sek) 01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 0.00 0.00
Other Income 157,000.00 105,000.00
Profit Loss From Operating Activities -76,699,000.00 -105,705,000.00
Finance Income 0.00 58,000.00
Finance Costs 110,000.00 1,418,000.00
Profit Loss Before Tax -76,809,000.00 -107,065,000.00
Income Tax Expense Continuing Operations -7,505,000.00 -7,860,000.00
Profit (loss) -69,304,000.00 -99,205,000.00
Profit Loss Attributable To Owners Of Parent -69,304,000.00 -99,205,000.00
Line item in (sek) 01.01.2022 02.01.2021 01.01.2023 02.01.2022
Profit (loss) -69,304,000.00 N/A -99,205,000.00 N/A
Adjustments For Increase Decrease In Trade Account Payable 1,436,000.00 N/A 182,000.00 N/A
Other Adjustments For Noncash Items 88,000.00 N/A 712,000.00 N/A
Interest Paid Classified As Operating Activities 110,000.00 N/A 119,000.00 N/A
Interest Received Classified As Operating Activities 0.00 N/A 47,000.00 N/A
Income Taxes Paid Refund Classified As Operating Activities -4,625,000.00 N/A -7,860,000.00 N/A
Cash Flows From Used In Operating Activities -64,997,000.00 N/A -117,555,000.00 N/A
Purchase Of Other Longterm Assets Classified As Investing Activities 6,000.00 N/A -27,000.00 N/A
Cash Flows From Used In Investing Activities -6,000.00 N/A 27,000.00 N/A
Proceeds From Issuing Shares 80,000,000.00 N/A 228,945,000.00 N/A
Payments Of Lease Liabilities Classified As Financing Activities 77,000.00 N/A 981,000.00 N/A
Cash Flows From Used In Financing Activities 74,323,000.00 N/A 200,712,000.00 N/A
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes 9,319,000.00 N/A 83,184,000.00 N/A
Effect Of Exchange Rate Changes On Cash And Cash Equivalents 130,000.00 N/A 1,063,000.00 N/A
Cash and cash equivalents 23,997,000.00 14,548,000.00 108,245,000.00 23,997,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
30.04.24 Jeppe Øvlesen Other Other SEK 499,995.40
30.04.24 Anders Kronborg Other Other SEK 299,993.80
21.03.24 Jeppe Øvlesen Other Other SEK 1,696,503.00
09.11.23 Thomas Jonassen Other Other SEK 22,072,775.00
09.11.23 Thomas Jonass Other Other SEK 13,507,656.25
16.01.23 Jeppe Øvlesen Other Other SEK 72,727,240.20
16.01.23 James Knight Other Other SEK 4,848,495.20
16.01.23 Thomas Boesen Other Other SEK 2,060,604.20
16.01.23 Torbjörn Bjerke Other Other SEK 961,223.00
16.01.23 Jeppe Øvlesen Other Other SEK 865,445.00

Capital markets information

ISIN

SE0008241491

LEI

549300RRYIEFEQ72N546

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.